Table 4.

Rating of risks, action and description for potential drug–drug interaction risk rating and action for potential drug–drug interaction

Classification (grade)	Action	Description
1	No known drug–drug interaction/no action needed	Discussed at MDT and no potential DDI identified
2	Advice on monitoring or counselling given by pharmacist	Discussed at MDT. Advice given by pharmacist regarding additional monitoring requirements/counselling points
3	Concomitant drug regimen changed	Discussed at MDT. Advice given regarding changing/omitting concomitant medications (excluding HIV drug regimens)
4	DDI with HIV/HCV regimen requiring a change in the HIV regimen or additional monitoring requirements	Discussed at MDT. Advice given regarding changing HIV regimen prior to commencing the hepatitis C treatment or additional monitoring requirements as a result of drug–drug interactions between the HIV/HCV regimens
5	HCV drug regimen changed	Discussed at MDT. Advice given regarding deviating from 1st line HCV regimen (in accordance with the current NHSE Run rate card at the time of treatment) due to drug–drug interactions

MDT multidisciplinary team, DDI drug–drug interactions, HIV human immunodeficiency virus, HCV hepatitis C virus, NHSE National Health Services England